Background: C1q/TNF-related protein isoform 15 (CTRP15) has been reported to be related to glucose and lipid metabolism, but the results are inconsistent. Metabolic syndrome (MetS) is a cluster of metabolic disorders. The aim of this study is to determine circulating CTRP15 levels in individuals with MetS and investigate the association among circulating CTRP15 and markers for MetS as well as insulin resistance.
| INTRODUCTION
Metabolic syndrome (MetS) is a cluster of metabolic disorders and associated with obesity, insulin resistance, hypertension, and dyslipidemia, and it increases risks for cardiovascular diseases (CVDs) and type 2 diabetes mellitus (T2DM). [1] [2] [3] [4] [5] In the past decade, the prevalence of MetS has increased to 34.7% in USA, and to 24.5% in China. 6, 7 MetS has led to a 1.5 to 2.5 fold increase in the mortality from CVD that makes a major public health problem today. 8 Thus, it is important to find biomarkers for predicting the development of MetS. Clinicians may use these biomarkers to screen for MetS patients in populations, especially in asymptomatic individuals.
C1q/TNF-related protein isoform 15 (CTRP15), or myonectin, belongs to the C1q/TNF-related protein family (C1QTNF isoform 5) and is a newly discovered myokine with metabolic functions. 9 The transcription of CTRP15 was induced in maturation myotubes, and it is mainly expressed in muscle tissues. 10 CTRP15 was found to be homologous with adiponectin (Adipoq) in the Q region, and it is thus considered to have a similar role as Adipoq. It has been reported that serum CTRP15 is related to the metabolic state in vivo. Fasting inhibits its release; however, feeding increases its gene expression and circulating levels. 11 Recently, it has been reported that CTRP15
regulates starvation-induced autophagy in the liver via activating the AKT kinase/the mammalian target of rapamycin signalling pathway.
This study also displays across-talk between muscle and liver to maintain energy balance. 10 However, there are conflicting reports regarding the relationship between CTRP15 and glucose/lipid metabolism.
One study showed that, in high-fat diet induced insulin resistant mice, CTRP15 expressions in adipocytes and hepatocytes and its circulating levels were low relative to normal mice, and CTRP15 treatment increased lipid uptake in adipocytes and hepatocytes through up-regulating expression of genes that promote lipid uptake. 11 Conversely, another study showed that circulating CTRP15 concentrations were increased in obese rats. 12 A third study found that serum CTRP15 levels were not affected by the high-fat diet. 9 Furthermore, Park et al found that CTRP15 treatment increased AMP-activated kinase phosphorylation and glucose uptake via increasing cell surface recruitment of glucose transporter-4. 13 These results indicate that CTRP15 might be closely related to metabolic balance and insulin resistance. However, the clinical association between circulating CTRP15 levels and MetS has not been reported. In the current study, we investigated the circulating levels of CTRP15 in MetS subjects and explored the relationship between circulating CTRP15 and the key components of MetS in a Chinese population.
| SUBJECTS AND METHODS

| Human participants
In the current study, we examined serum CTRP15 concentrations in 
| Measurements of serum CTRP15
The circulating levels of CTRP15 were measured using ELISA kits obtained from Aviscera Bioscience Inc (USA, Catalogue No.
SK00393-19)
, following the manufacture's protocol. The limit of detection for this kit was 31.25 ng/mL, and intra-assay and inter-assay variations were < 8% and < 12%, respectively. The ELISA kit had been validated by the dealer, showing high sensitivity and excellent specificity for detection of human CTRP15, and no any cross-reactivity with other CTRPs.
| Anthropometric and biochemical examinations
After an overnight fasting for 10 to 12 hours, BMI, WC, and BP were measured, and blood was drawn for biochemical measurements, including FBG, oral glucose tolerance test (OGTT) glucose, HbA1c, insulin, TG, total cholesterol (TC), free fatty acids (FFA), HDL-C, and low-density lipoprotein cholesterol (LDL-C) as indicated previously. 17 An OGTT was performed in all study individuals as reported previously. 18 The percentage of fat in vivo (FAT%) was examined by using bioelectrical impedance (BIA-101; RJL Systems, Shenzhen, China).
Insulin resistance was estimated using homeostasis model assessment index (HOMA-IR). 18 Insulin sensitivity index (ISI) was calculated as previously reported. 19, 20 The area under the curve for glucose (AUC glucose ) during the OGTT was calculated geometrically following the trapezoidal rule by using SPSS 19.0 (Chicago, IL, USA). 21 
| Statistical analysis
Statistical analyses were carried out by SPSS 19.0. Data were expressed as mean ± SD or median with inter quartile range. Data of non-normal distribution, as determined using Kolmogorov-Smirnov test, were logarithmically transformed before analysis. Comparisons between groups were performed with independent student t test.
Relationships between CTRP15 and other variables were calculated by simple, partial, and multiple correlation coefficients. Multiple linear regression was carried out to assess variables that had independent associations with circulating CTRP15 and included all variables related to circulating CTRP15. Binary logistic regression analyses were used to examine the association between the serum CTRP15 and MetS.
Receiver operating characteristic (ROC) curve was plotted by SPSS 19.0 for evaluating the sensitivity and specificity of CTRP15 to predict the MetS. Sample size was calculated using the following equations:
Compared to the controls, P < 0.05 was considered significant.
3 | RESULTS
| Circulating CTRP15 levels and its distribution in healthy individuals
The distribution of serum CTRP15 levels in healthy adults was shown in Figure 1A . We found that serum CTRP15 levels were from 20.16 to 79.82 μg/L for most healthy adults (84.2%) with a mean circulating CTRP 15 levels at 53.7 ± 26.1 μg/L.
| Serum CTRP15 levels and its association with other parameters in MetS individuals
Main clinical features of the MetS and control individuals are shown in Table 1 for CDS criteria and Table S1 for NCEP ATP III criteria. The number of MetS was 119 based on CDS criteria and 157 according to NCEP ATP III criteria, respectively. As expected, MetS individuals had higher BMI, WHR, BP, FAT(%), TG, 2 h-BG, fasting insulin (FIns), 2-h plasma insulin after glucose overload (2 h-Ins), HbA1c, HOMA-IR and AUC glucose , and lower HDL-C and ISI than the controls (P < 0.05 or P < 0.01). In all study population, serum CTRP15 levels were higher in obese subjects than in lean subjects (71.7 ± 12.1 vs 58.9 ± 17.8 μg/L; P < 0.05, Figure 1B ), but no difference between healthy and overweight subjects. Importantly, serum CTRP15 levels were higher in MetS subjects than in healthy controls (P < 0.01, Table 1 and Figure 1C ). After adjustment for sex and age, this difference remained significant (Table 1) .
In linear regression analysis, the results showed that serum CTRP15 correlated positively with WHR, BMI, systolic blood pressure (SBP), FAT %, 2 h-BG, FIns, 2 h-Ins, TG, FFA, HbA1c, HOMA-IR, and AUC glucose , while negatively with HDL-C and ISI in all study populations (Table 2 ). After adjusted age and WHR, Serum CTRP15 were still significantly related to these parameters. Multivariate regression analyses
showed that HOMA-IR and HDL-C were independently related factors influencing serum CTRP15 concentrations ( Table 2 ). The regression equation was: Y CTRP15 = 62.729 + 1.968X HOMA-IR -13.946X HDL-C (R 2 = 0.111, P < 0.01). There was no significant difference between the CDS and NCEP ATP III criteria in correlation analysis (Table S2 ).
In addition, binary logistic regression analysis showed that serum CTRP15 concentrations were significantly related to MetS, even after controlling for anthropometric variables, age, gender, blood lipid, and so on ( Table 3) . The same results were also obtained by using NCEP ATP III diagnostic criteria (Table S3 ).
In all study population, regression analyses of all-factor and stepwise models indicated that the main predictor of serum CTRP15 was HOMA-IR ( Figure 1D ). In order to further analyse the relationship between CTRP15 and IR, individuals were divided into IR (HOMA-IR > 3) and non-IR (HOMA-IR ≤ 3). 22 As shown in Figure 1E , serum CTRP15 levels were significantly higher in IR subjects than in non-IR subjects (67.5 ± 3.5 vs 57.7 ± 1.6 μg/L, P < 0.01 Figure 1E ).
FIGURE 1 Analysis of circulating CTRP15 by different statistical approaches. A, Distribution of circulating concentration of CTRP15 in 222 healthy individuals; B, circulating CTRP15 levels in lean, over-weight, and obese subjects; C, circulating CTRP15 levels in Mets and control subjects; D, all factors and stepwise multiple regression analyses of the circulating CTRP15 and MetS in study subjects; E, circulating CTRP15 levels in insulin resistance and control subjects; F, the odds ratio of having MetS in different tertiles of circulating CTRP15; G, circulating CTRP15 levels in relation to the number of MetS components. Data are expressed as means ± SD. *P < 0.05, ** P < 0.01
| The relationship between increased CTRP15 concentration and MetS as well as the number of components of the MetS
The row mean score and the Cochran-Armitage trend test showed that elevated CTRP15 levels displayed a linear trend and were independently related to MetS (Table S4 ). The results were also very similar to those analysed by NCEP ATP III diagnostic criteria (Table S5) .
Additionally, in all study individuals, we divided serum CTRP15 into three tertiles (tertile 1, < 58.2 μg/L; tertile 2, 58.2-64.8 μg/L; tertile 3, > 64.8 μg/L) and calculated the odds of developing MetS by logistic regression analysis. In the tertile 2 and tertile 3 of serum CTRP15, the odds ratios of developing MetS were higher than tertile 1(95% CI 1.74; 6.62 μg/L for tertile 2 and 95% CI 4.49; 16.73 μg/L for tertile 3; vs tertile 1,both P < 0.01; Figure 1F ).
We next stratified the mean concentrations of circulating CTRP15
according to the number of components of the MetS. As shown in Figure 1G , circulating CTRP15 increased progressively with increasing number of the MetS components (P for trend <0.01).
| Receiver operating characteristic (ROC) curve analysis
To investigate the predictive value of CTRP15 for MetS and IR, we analysed the ROC curves of circulating CTRP15. The results analysed by the CDS criteria revealed that the area under the ROC curves (AUC MetS ) was 0.75 (P < 0.001) with a sensitivity of 71%, and specificity of 73% for MetS (Figure 2A ) and the ROC curves (AUC IR ) was 0.64 (P < 0.001) with a sensitivity of 65% and specificity of 64% for IR ( Figure 2B ). The best cutoff values for circulating CTRP15 to predict MetS and IR were 63.6 and 64.0 μg/L. For NCEP ATP III diagnostic criteria, AUC MetS was 0.85 (P < 0.01) with a sensitivity of 80%, and specificity of 82% for MetS, while the results of ROC for IR analysis were similar to that of CDS criteria ( Figure S1 ).
| DISCUSSION
In the current study, we demonstrate that serum CTRP15 levels were significantly increased in MetS individuals and individuals with increasing number of MetS components such as insulin resistance, hypertension, and central obesity. These results suggest that CTRP15 may be a circulating biomarker for MetS and insulin resistance-related metabolic diseases. Recent studies have shown that circulating CTRP15 concentrations and its gene expression are subject to metabolic effects. 23 In addition, in support of our results, animal studies revealed that serum Values are given as mean ± SD or median (inter quartile range).
Abbreviations: AUC glucose , the area under the curve for glucose; BMI, body mass index; CTRP15, C1q/TNF-related protein isoform 15; DBP, diastolic blood pressure; FAT(%), the percentage of fat in vivo; FBG, fasting blood glucose; FFA, free fatty acid; FIns, fasting plasma insulin; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; ISI, insulin sensitivity index; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride; WHR, waist hip ratio; 2 h-BG, 2 h post-glucose load blood glucose; 2 h-Ins, 2-h plasma insulin after glucose overload. CTRP15 concentrations increased significantly in obese/diabetic animals. 11, 13 Although the molecular mechanism for the increased CTRP15
concentrations in MetS subjects is still unclear, it is possible that the upregulation of CTRP15 is caused by changes in biosynthesis in response to metabolic disorder in MetS individuals. In addition, it is also possible that obesity may lead to CTRP15 resistance, like leptin and insulin resistance in obese subjects, resulting in its compensatory up-regulation.
However, further studies are needed to explore why circulating CTPR15 levels are elevated in MetS individuals.
In the current study, two diagnostic criteria were used (CDS and NCEP ATP III criteria) to analyse the relationship between CTRP15
and metabolic parameters as well as MetS. The results showed that circulating CTRP15 concentrations were significantly associated with the number of MetS components, WHR and BMI. The strongest associations were AUC glucose , ISI and CTRP15. When we divided all subjects into insulin resistance (HOMA-IR > 3) and non-insulin resistance (HOMA-IR ≤ 3), 22 the result showed that circulating CTRP15 levels were higher in insulin resistant subjects than in non-insulin resistant subjects. This finding further suggests that circulating CTRP15 is related to insulin resistance in MetS subjects. In addition, the results also showed that circulating CTRP15 correlated with parameters of adiposity (WHR, BMI, and FAT%), insulin resistance shown that overnight fasting decreased, whereas re-feeding elevated CTRP15 mRNA and serum levels in mice. 23 These data suggest that the release of CTRP15 is highly responsive to an acute change in the metabolic state in vivo after nutrient intake. Therefore, CTRP15 may be a nutrient-responsive cytokine.
To investigate the association between CTRP15 and MetS, we stratified the concentrations of circulating CTRP15 by the number of MetS components. The result showed that CTRP15 levels were significantly increased with more number of MetS components. This suggests that each component of MetS increases circulating CTRP15 levels. The super position of these components leads to higher CTRP15 levels in vivo. Therefore, high levels of CTRP15 may reflect the severity of metabolic disorders in MetS subjects. Finally, we performed a ROC analysis to explore the optimal cut-off value of circulating CTRP15 for the prediction of insulin resistance and MetS. Data from ROC analysis showed that serum CTRP15 is a predictor for both insulin resistance and MetS. We therefore believe that the relationship between CTRP15 and MetS is due to the high prevalence of IR in these individuals. When comparing two diagnostic criteria, analysis using the NCEP ATP III criteria has greater AUC MetS value and higher specificity and Results of binary logistic regression analysis are presented. 95% CI, confidence interval; OR, odds ratio. Data from two subject groups were pooled to calculate logistic regression.
FIGURE 2 A, ROC curve analysis of the prediction of Mets; B, ROC curve analysis of the prediction of insulin resistance sensitivity than CDS criteria. In fact, in the current study cohort, the NCEP ATP III criteria screened more MetS patients than CDS criteria (119 for CDS and 157 for NCEP ATP III). Therefore, these data suggest that NCEP ATP III is better than CDS criteria for MetS screening.
In a previous study, we reported that circulating Sfrp5, an adipokine, was significantly lower in MetS individuals, and it may predict MetS. 24 In the current study, we observed that serum CTRP15 level was significantly higher in MetS individuals and was a positive predictor for MetS. Therefore, when an individual has a high circulating CTRP15 and a low Sfrp5 levels, it is more likely to diagnose MetS.
Our results are subject to the following limitations: (1) the crosssectional design of the study cannot elucidate the causal relationship between CTRP15 and MetS. Therefore, longitudinal intervention studies and future investigation are necessary; (2) our samples are entirely from Chinese people. Therefore, these results should be carefully extrapolated to other ethnic groups; (3) our data were also limited by a somewhat small sample size, although the number of subjects in this study provide more than 90% power to demonstrate association at the conventional α <0.05 level, we believe that our study remains sufficient to demonstrate a novel association of serum CTRP15 with MetS in study subjects.
In conclusions, our data provide clinical evidence that the increase of serum CTRP15 level may have a potential role in the pathogenesis of MetS and it may be related to metabolic disorders and insulin resistance. In addition, the relationship between serum CTRP15 concentrations and the key components of MetS indicates that CTRP15
can be potentially used as a circulating biomarker for risk prediction of CVD in obese and T2DM individuals. Therefore, this study would be a pilot study, and follow-up study is needed to investigate whether CTRP15 is a novel therapeutic target for obesity or insulin resistancerelated diseases, such as CVD and T2DM.
